1
|
Li LQ, Su TS, Wu QY, Lin ZT, Liang SX. Therapeutic Outcome of Stereotactic Body Radiotherapy for Small Hepatocellular Carcinoma Lesions - A Systematic Review and Network Meta-analysis. Clin Oncol (R Coll Radiol) 2023; 35:652-664. [PMID: 37541936 DOI: 10.1016/j.clon.2023.07.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2023] [Revised: 03/15/2023] [Accepted: 07/10/2023] [Indexed: 08/06/2023]
Abstract
Surgical resection, stereotactic body radiotherapy (SBRT) and radiofrequency ablation (RFA) have seldom been compared for small hepatocellular carcinoma (HCC). We explored the treatment outcomes of SBRT for small HCC by conducting a network meta-analysis (NMA). We compared the efficacy and safety of surgical resection, RFA and SBRT for liver-confined small HCC (three or fewer lesions with a diameter ≤5 cm). The study endpoint included the odds ratios of the 1-, 3- and 5-year progression/recurrence/disease-free survival (disease progression-free survival; DPFS) and overall survival rates, as well as severe complications. Forty-five studies included 21 468 patients. In the NMA with comparable data, SBRT had comparable 1-, 3- and 5-year DPFS but significantly worse pooled long-term overall survival (3- and 5-year overall survival) than surgical resection (odds ratio 1.39, 95% confidential interval 1.3-1.89; odds ratio 1.33, 95% confidence interval 1.06-1.69, respectively). SBRT was associated with significantly better pooled 1-year DPFS compared with RFA (odds ratio 0.39, 95% confidence interval 0.15-0.97), with the remaining outcomes being comparable. SBRT had significantly less incidence of severe complications compared with surgical resection (odds ratio 0.62, 95% confidence interval 0.42-0.88) and RFA (odds ratio 0.2, 95% confidence interval 0.03-0.94). In conclusion, for small HCCs (≤5 cm) with one to three nodules, SBRT may be favourable to reduce the risks of severe complications. In terms of DPFS, SBRT may be recommended as an alternative first-line therapy for RFA and surgical resection. The results regarding overall survival should be interpreted with caution, considering the potentially uneliminated bias. There is a clear need for well-designed randomised trials to conclusively identify real differences in efficacy between these treatments, especially SBRT and surgical resection.
Collapse
Affiliation(s)
- L-Q Li
- Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi Zhuang Autonomous Region, China
| | - T-S Su
- Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi Zhuang Autonomous Region, China
| | - Q-Y Wu
- Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi Zhuang Autonomous Region, China
| | - Z-T Lin
- Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi Zhuang Autonomous Region, China
| | - S-X Liang
- Department of Radiation Oncology, Guangxi Medical University Cancer Hospital, Nanning, Guangxi Zhuang Autonomous Region, China.
| |
Collapse
|
2
|
Tang Z, Tang Y, Li L, Liu T, Yang J. Limonin provokes hepatocellular carcinoma cells with stemness entry into cycle via activating PI3K/Akt signaling. Biomed Pharmacother 2019; 117:109051. [DOI: 10.1016/j.biopha.2019.109051] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2019] [Revised: 05/21/2019] [Accepted: 05/30/2019] [Indexed: 12/12/2022] Open
|
3
|
Chen K, Wei H, Pan J, Chen Z, Pan D, Gao T, Huang J, Huang M, Ou M, Zhong W. Six1 is negatively correlated with poor prognosis and reduces 5-fluorouracil sensitivity via attenuating the stemness of hepatocellular carcinoma cells. Eur J Pharmacol 2019; 861:172599. [PMID: 31404537 DOI: 10.1016/j.ejphar.2019.172599] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2019] [Revised: 08/04/2019] [Accepted: 08/08/2019] [Indexed: 12/17/2022]
Abstract
The promoting roles of transcriptional factor six1 have been shown in various tumors, such as breast cancer and colorectal Cancer. However, its roles in hepatocellular carcinoma (HCC) cell stemness and chemotherapeutic sensitivity are never been revealed. In the present study, we showed that six1 expression was negatively correlated the overall survival of HCC patients and significantly increased in HCC tissues. Analysis on normal hepatic cells and HCC cells obtained the consistent result. Functional experiments revealed that six1 knockdown enhanced 5-fluorouracil (5-FU) sensitivity and reduced the stemness of HCC cells. Additionally, six1 knockdown partially reversed 5-FU resistance and attenuated the stemness in 5-FU-resistant HCC cells. Furthermore, we demonstrated that six1 directly bound to sox2 (a stemness master regulator) promoter, enhanced its transcription and expression. Overexpression of sox2 rescued the inhibitory effects of six1 knockdown on the stemness and 5-FU sensitivity of HCC cells. Thus, our work identified a novel six1/sox2 axis in regulating the stemness of HCC cells.
Collapse
Affiliation(s)
- Kehe Chen
- Department of Chemotherapy Division II in Clinical Tumor Center, The People's Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning City, Guangxi Zhuang Autonomous Region, 530021, China.
| | - Haiming Wei
- Department of Pathology, The People's Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning City, Guangxi Zhuang Autonomous Region, 530021, China
| | - Jinfei Pan
- Department of Hepatobiliary Surgery, The People's Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning City, Guangxi Zhuang Autonomous Region, 530021, China
| | - Zhenxiang Chen
- Department of Chemotherapy Division II in Clinical Tumor Center, The People's Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning City, Guangxi Zhuang Autonomous Region, 530021, China
| | - Deng Pan
- Department of Chemotherapy Division II in Clinical Tumor Center, The People's Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning City, Guangxi Zhuang Autonomous Region, 530021, China
| | - Ting Gao
- Department of Chemotherapy Division II in Clinical Tumor Center, The People's Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning City, Guangxi Zhuang Autonomous Region, 530021, China
| | - Jingning Huang
- Department of Chemotherapy Division II in Clinical Tumor Center, The People's Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning City, Guangxi Zhuang Autonomous Region, 530021, China
| | - Min Huang
- Department of Chemotherapy Division II in Clinical Tumor Center, The People's Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning City, Guangxi Zhuang Autonomous Region, 530021, China
| | - Mei Ou
- Department of Chemotherapy Division II in Clinical Tumor Center, The People's Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning City, Guangxi Zhuang Autonomous Region, 530021, China
| | - Wenhe Zhong
- Department of Chemotherapy Division II in Clinical Tumor Center, The People's Hospital of Guangxi Zhuang Autonomous Region, No. 6 Taoyuan Road, Nanning City, Guangxi Zhuang Autonomous Region, 530021, China
| |
Collapse
|
4
|
Rajyaguru DJ, Borgert AJ, Halfdanarson TR, Truty MJ, Kurup AN, Go RS. Reply to E.L. Pollom et al, N. Ohri et al, A. Fiorentino et al, D.R. Wahl et al, N. Kim et al, J. Boda-Heggemann et al, S. Rana et al, N. Sanuki et al, J.R. Olsen et al, G.L. Smith et al, and A. Shinde et al. J Clin Oncol 2018; 36:2567-2569. [PMID: 29945519 DOI: 10.1200/jco.2018.78.6418] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Affiliation(s)
- Devalkumar J Rajyaguru
- Devalkumar J. Rajyaguru, Gundersen Health System, La Crosse, WI; Andrew J. Borgert, Gundersen Lutheran Medical Foundation, La Crosse, WI; and Thorvardur R. Halfdanarson, Mark J. Truty, A. Nicholas Kurup, and Ronald S. Go, Mayo Clinic, Rochester, MN
| | - Andrew J Borgert
- Devalkumar J. Rajyaguru, Gundersen Health System, La Crosse, WI; Andrew J. Borgert, Gundersen Lutheran Medical Foundation, La Crosse, WI; and Thorvardur R. Halfdanarson, Mark J. Truty, A. Nicholas Kurup, and Ronald S. Go, Mayo Clinic, Rochester, MN
| | - Thorvardur R Halfdanarson
- Devalkumar J. Rajyaguru, Gundersen Health System, La Crosse, WI; Andrew J. Borgert, Gundersen Lutheran Medical Foundation, La Crosse, WI; and Thorvardur R. Halfdanarson, Mark J. Truty, A. Nicholas Kurup, and Ronald S. Go, Mayo Clinic, Rochester, MN
| | - Mark J Truty
- Devalkumar J. Rajyaguru, Gundersen Health System, La Crosse, WI; Andrew J. Borgert, Gundersen Lutheran Medical Foundation, La Crosse, WI; and Thorvardur R. Halfdanarson, Mark J. Truty, A. Nicholas Kurup, and Ronald S. Go, Mayo Clinic, Rochester, MN
| | - A Nicholas Kurup
- Devalkumar J. Rajyaguru, Gundersen Health System, La Crosse, WI; Andrew J. Borgert, Gundersen Lutheran Medical Foundation, La Crosse, WI; and Thorvardur R. Halfdanarson, Mark J. Truty, A. Nicholas Kurup, and Ronald S. Go, Mayo Clinic, Rochester, MN
| | - Ronald S Go
- Devalkumar J. Rajyaguru, Gundersen Health System, La Crosse, WI; Andrew J. Borgert, Gundersen Lutheran Medical Foundation, La Crosse, WI; and Thorvardur R. Halfdanarson, Mark J. Truty, A. Nicholas Kurup, and Ronald S. Go, Mayo Clinic, Rochester, MN
| |
Collapse
|